<DOC>
	<DOCNO>NCT00312819</DOCNO>
	<brief_summary>Recent study laboratory animal demonstrate ability disulfiram significantly inhibit growth metastasis mouse model lung cancer . Work cell vitro support idea inhibition mainly due inhibition angiogenesis - formation new blood vessel tumor . Furthermore , find best effect obtain disulfiram use high dose optimal dose , small . Thus , trial ass addition disulfiram chemotherapy non-small cell lung cancer ( NSCLCA ) .</brief_summary>
	<brief_title>Initial Assessment Effect Addition Disulfiram ( Antabuse ) Standard Chemotherapy Lung Cancer</brief_title>
	<detailed_description>Metastatic non small cell lung cancer remain deadly disease median survival time several month . Any treatment prolong patient ' survival without cause severe side effect course important addition limit arsenal fight disease . A recent article Marikowsky colleague extend significantly knowledge regard possible activity disulfiram ( well know commercial name Antabuse ) anticancer agent ( Marikowsky et al Int J cancer 97 :34 2002 ) . In article demonstrate disulfiram potent antitumor activity act significant inhbitor angiogenesis . Since disulfiram well tolerated thousand patient , observation anti angiogenic therapy enhances effect chemotherapy ( example bevacizumab combination chemotherapy colon carcinoma ) decide conduct clinical trial assess effect addition drug moderate dos chemotherapy use one standard therapy lung cancer . In order obtain information regard effect addition drug , 50 % patient treat drug rest treat placebo .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disulfiram</mesh_term>
	<criteria>Metastatic nonsmall cell lung cancer Previously untreated ECOG performance status ( PS ) 01 Liver function test within norm Over 18 Willingness abstain alcohol Not pregnant Without psychiatric history</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Non-small cel lung cancer</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>randomize phaseII</keyword>
	<keyword>disulfiram</keyword>
	<keyword>antiangiogenesis</keyword>
	<keyword>placebo</keyword>
</DOC>